ArticleJournal of translational medicine2026
The role and underlying mechanism of FABP4 dysregulation mediated by m6A modification in unexplained recurrent spontaneous abortion.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in m6A Modification in Pregnancy-Related Disorders and Female Reproductive Endocrine Diseases.Expert reviews in molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundUnexplained recurrent spontaneous abortion (URSA) poses a significant clinical challenge with an elusive pathogenesis. FABP4 is crucial for lipid homeostasis and placental development, but its specific role and regulatory mechanism in URSA remain unclear.
methodsFABP4 expression was analyzed in human placental tissues from URSA patients and control groups. The functional role of FABP4 was investigated using Fabp4-knockout mouse models and trophoblast cell lines. Mechanistic studies employed Seahorse metabolic analysis, Raman spectroscopy, methylated RNA immunoprecipitation qPCR (MeRIP-qPCR), and single-cell RNA sequencing to assess mitochondrial function and lipid metabolism.
resultsFABP4 was significantly down-regulated in placental tissues from URSA patients. In vivo and in vitro models confirmed that FABP4 deficiency leads to trophoblast dysfunction. Mechanistically, FABP4 expression was regulated by m6A methylation modifications. Downregulation of the m6A demethylase FTO increased m6A levels on FABP4 mRNA, inhibiting its expression. Concurrently, downregulation of the m6A reader IGF2BP3 reduced FABP4 mRNA stability. This dysregulation of FABP4 disrupted intracellular lipid homeostasis in trophoblast cells, leading to suppressed mitochondrial oxidative phosphorylation, activated oxidative stress, and inhibited SOD2 expression, ultimately contributing to the pathogenesis of URSA.
conclusionsThis study identifies FABP4 deficiency as a critical event in URSA pathogenesis, driven by an m6A-mediated epigenetic mechanism involving FTO and IGF2BP3. FABP4 downregulation disrupts trophoblast lipid metabolism and mitochondrial function. These findings offer novel insights into URSA and suggest FABP4 as a potential therapeutic target for clinical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.